Emil Lou, MD, PhD, has been named to the 2026 TIME100 Health List of the world’s most influential health leaders, an honor that recognizes individuals driving major advances in medicine and science. He also has longstanding ties to the Clinical and Translational Science Institute (CTSI) through both its scholar and mentoring programs.
Dr. Lou began his CTSI involvement as an awardee in the KL2 Scholars Career Development Program, where he received early career support for his research. He has since remained engaged with CTSI by serving as a mentor to trainees in the TL1 program (now known as the T32 Program) and the Translational Research Development Program, helping support the development of future translational researchers.
Celebrated nationally for advancing cancer research
The TIME100 Health List recognized Dr. Lou for his innovative approach to translational research in oncology. He led a first-in-human clinical trial that used CRISPR/Cas9 gene editing to help the immune system target advanced gastrointestinal cancers.
Published in The Lancet Oncology, the study points to a promising new direction for patients with late-stage disease. It also underscores the importance of translational science that bridges laboratory discovery and clinical care.
He was also an early adopter of using social media to share emerging scientific findings, helping broaden the reach of new research and engage scientific and clinical communities.
A decade of partnership with CTSI’s training and mentorship programs
For more than a decade, Dr. Lou has contributed to CTSI’s education and training efforts while advancing his own translational research program. His long-term involvement reflects CTSI’s role in supporting researchers at multiple stages of their careers. This recognition as part of the TIME100 Health List highlights the value of these sustained partnerships in advancing health in Minnesota and beyond.
Related Stories
